4-[(S)-4-Boc-2-methyl-1-piperazinyl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methyl-3-pyridyl)pyrido[2,3-d]pyrimidin-2(1H)-one
98%
- Product Code: 232859
CAS:
2252403-85-1
| Molecular Weight: | 606.6628 g./mol | Molecular Formula: | C₃₂H₃₆F₂N₆O₄ |
|---|---|---|---|
| EC Number: | MDL Number: | MFCD32068509 | |
| Melting Point: | Boiling Point: | 703.6±70.0 °C(Predicted) | |
| Density: | 1.33±0.1 g/cm3(Predicted) | Storage Condition: | 2-8°C |
Product Description:
Used as a key intermediate in the synthesis of Janus kinase (JAK) inhibitors, particularly in the development of targeted therapies for inflammatory and autoimmune diseases such as rheumatoid arthritis and psoriasis. Its structural features enable selective modulation of JAK enzyme activity, contributing to reduced cytokine signaling and inflammation. The compound’s design supports improved pharmacokinetic properties, including metabolic stability and oral bioavailability, making it valuable in optimizing drug candidates for clinical use.
Product Specification:
| Test | Specification |
|---|---|
| Appearance | Off-white to Gray Solid |
| Purity (%) | 97.5-100 |
| LCMS | Conforms to Structure |
| NMR | Conforms to Structure |
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 0.100 | 10-20 days | £109.70 |
+
-
|
| 0.250 | 10-20 days | £182.83 |
+
-
|
| 0.500 | 10-20 days | £255.96 |
+
-
|
| 1.000 | 10-20 days | £365.66 |
+
-
|
4-[(S)-4-Boc-2-methyl-1-piperazinyl]-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methyl-3-pyridyl)pyrido[2,3-d]pyrimidin-2(1H)-one
Used as a key intermediate in the synthesis of Janus kinase (JAK) inhibitors, particularly in the development of targeted therapies for inflammatory and autoimmune diseases such as rheumatoid arthritis and psoriasis. Its structural features enable selective modulation of JAK enzyme activity, contributing to reduced cytokine signaling and inflammation. The compound’s design supports improved pharmacokinetic properties, including metabolic stability and oral bioavailability, making it valuable in optimizing drug candidates for clinical use.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
£0.00
£0.00
Total :